Provided By GlobeNewswire
Last update: Jul 22, 2025
CARSON CITY, Nev., July 22, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the appointment of Amy S. Chappell, MD, FAAN, and Kameel D. Farag to its Board of Directors.
Read more at globenewswire.com1.65
+0.05 (+3.12%)
Find more stocks in the Stock Screener